{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:52:34Z","timestamp":1790031154555,"version":"4.0.1"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0133452","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T18:05:31Z","timestamp":1437501931000},"page":"e0133452","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa"],"prefix":"10.1371","volume":"10","author":[{"given":"Theresa M.","family":"Rossouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute D.","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Melikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"van Dyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winifred","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette M.","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theunis","family":"Avenant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"R Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1001273","DOI":"10.1371\/journal.pmed.1001273","article-title":"Treatment of young children with HIV infection: using evidence to inform policymakers","volume":"9","author":"AJ Prendergast","year":"2012","journal-title":"PLoS Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1056\/NEJM199705083361901","article-title":"Viral load and disease progression in infants infected with human immunodeficiency virus type 1","volume":"336","author":"WT Shearer","year":"1997","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/515596","article-title":"Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants","volume":"178","author":"EJ Abrams","year":"1998","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/ciq161","article-title":"Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children","volume":"52","author":"A Moorthy","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref6","unstructured":"Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, et al. Nevirapine (NVP) vs lopinavir-ritonavir (LPV\/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa (19\u201322 July 2009). Abstract LBPEB12. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.aids2014.org\/Abstracts\/A200722769.aspx\" xlink:type=\"simple\">https:\/\/www.aids2014.org\/Abstracts\/A200722769.aspx<\/ext-link>"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcv.2010.03.017","article-title":"Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART","volume":"48","author":"IJ Macleod","year":"2010","journal-title":"J Clin Virol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/COH.0b013e3283339bd8","article-title":"Sequencing of antiretroviral therapy in children in low- and middle-income countries","volume":"5","author":"A Sohn","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 1","key":"ref9","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2334-14-S1-S5","article-title":"Tuberculosis and HIV co-infection in children","volume":"14","author":"E Venturini","year":"2014","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa0800971","article-title":"Early antiretroviral therapy and mortality among HIV-infected infants","volume":"359","author":"A Violari","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ije\/dym104","article-title":"Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis","volume":"36","author":"E Arrive","year":"2007","journal-title":"Int J Epidemiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1000931","article-title":"Antiretroviral treatment for children with peripartum nevirapine exposure","volume":"363","author":"P Palumbo","year":"2010","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa1113249","article-title":"Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children","volume":"366","author":"A Violari","year":"2012","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"World Health Organization (2013) Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/download\/en\/index.html\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/download\/en\/index.html<\/ext-link>. Accessed 10 December 2013."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"CJ La Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e17273","DOI":"10.1371\/journal.pone.0017273","article-title":"Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment","volume":"6","author":"C Frohoff","year":"2011","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is insufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis","volume":"16","author":"H McIlleron","year":"2011","journal-title":"Antivir Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment Optimization in Patients Co-Infected with HIV and <italic>Mycobacterium tuberculosis<\/italic> Infections: Focus on Drug\u2013Drug Interactions with Rifamycins","volume":"53","author":"M Regazzi","year":"2014","journal-title":"Clinical Pharmacokinetics"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3851\/IMP1455","article-title":"Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries","volume":"14","author":"G Maartens","year":"2009","journal-title":"Antivir Ther"},{"key":"ref20","unstructured":"South African National Department of Health: Guidelines for the Management of HIV in Children, 2nd Edition 2010. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sahivsoc.org\/upload\/documents\/Guidelines_for_Management_of_HIV_in_Children_2010.pdf\" xlink:type=\"simple\">http:\/\/www.sahivsoc.org\/upload\/documents\/Guidelines_for_Management_of_HIV_in_Children_2010.pdf<\/ext-link>. Accessed 23 October 2012."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2011.0284","article-title":"Primary drug resistance in South Africa: data from 10 years of surveys","volume":"28","author":"J Manasa","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref22","unstructured":"World Health Organization (2006) WHO Multicentre Growth Reference Study Group: WHO child growth standards: length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/childgrowth\/standards\/technical_report\/en\/ index.html\" xlink:type=\"simple\">http:\/\/www.who.int\/childgrowth\/standards\/technical_report\/en\/ index.html<\/ext-link>. Accessed 20 March 2015."},{"key":"ref23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.qai.0000197070.69859.f3","article-title":"Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview","volume":"41","author":"JA Bartlett","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","article-title":"Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis","volume":"26","author":"O Ajose","year":"2012","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-na\u00efve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"JM Molina","year":"2008","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","author":"E Lathouwers","year":"2011","journal-title":"Antivir Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.inf.0000055061.97567.34","article-title":"Forty-eight-week evaluation of lopinavir\/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children","volume":"22","author":"X S\u00e1ez-Llorens","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"ref28","unstructured":"Riddick A, Moultrie H, Kuhn L, Fairlie L, Chersich M, Meyers T. Genotypic resistance profiles among HIV-1 infected children failing antiretroviral treatment at Chris Hani Baragwanath Hospital, Soweto, South Africa. Proceedings of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa (July 19\u201322, 2009). Abstract WEPEB213. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/biblio.ugent.be\/publication\/817613\" xlink:type=\"simple\">https:\/\/biblio.ugent.be\/publication\/817613<\/ext-link>"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-11-3","article-title":"Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort","volume":"11","author":"S Pillay","year":"2014","journal-title":"AIDS Res Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/apc.2007.0200","article-title":"Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy","volume":"22","author":"A Agwu","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(10)70313-3","article-title":"First-line antiretroviral therapy with a protease inhibitor versus nonnucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2\/3 trial","volume":"11","author":"A Babiker","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"for the AIDS Clinical Trials Groups Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"SA Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181af5a00","article-title":"Emergence of drug resistance in HIV-1 subtype C infected children failing the South African National Antiretroviral Roll-Out Program","volume":"28","author":"CL Wallis","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3851\/IMP2015","article-title":"The prevalence of darunavir-associated mutations in HIV-1 infected children in the UK","volume":"17","author":"KL Donegan","year":"2012","journal-title":"Antivir Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dks310","article-title":"Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting","volume":"67","author":"AI Maiga","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.332.7551.1183","article-title":"Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997\u20132005: cohort study","volume":"332","author":"EN Menson","year":"2006","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/01.inf.0000177281.93658.df","article-title":"Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age","volume":"24","author":"EG Chadwick","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1542\/peds.2005-1272","article-title":"Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort","volume":"117","author":"HJ Scherpbier","year":"2006","journal-title":"Pediatrics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2431-10-56","article-title":"Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study","volume":"10","author":"PM Musoke","year":"2010","journal-title":"BMC Pediatr"},{"issue":"suppl 4","key":"ref40","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1093\/cid\/cis006","article-title":"Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization\u2019s Generic Protocol in Maputo, Mozambique","volume":"54","author":"P Vaz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref41","unstructured":"Weigel R, Buck WC, Kang\u2019ombe AR, Geretti AM, Andrianarimanana DK, Ng\u2019ambi W, et al. (2014) HIV drug resistance in children starting ART: baseline surveillance results from Malawi. WEPE138\u2014Poster Exhibition. 20<sup>th<\/sup> International AIDS Conference. Melbourne, Australia. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aids2014.org\/\" xlink:type=\"simple\">http:\/\/www.aids2014.org\/<\/ext-link>. Accessed 20 December 2014."},{"issue":"Suppl 4","key":"ref42","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.7448\/IAS.15.6.18085","article-title":"Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection","volume":"15","author":"A Violari","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/QAD.0b013e328345e56b","article-title":"Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy","volume":"25","author":"A Prendergast","year":"2011","journal-title":"AIDS"},{"key":"ref44","first-page":"96","article-title":"Excess mortality risk associated with HIV infection in a large Malawi nutritional rehabilitation unit","volume":"19","author":"M Kerac","year":"2007","journal-title":"Malawi Med J"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/peds.2009-2701","article-title":"Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries","volume":"127","author":"E Peacock-Villada","year":"2011","journal-title":"Pediatrics"},{"key":"ref46","first-page":"71","article-title":"Weight as predictors of clinical progression and treatment failure: results from the TREAT Asia Pediatric HIV Observational Database","volume":"67","author":"A Kariminia","year":"2014","journal-title":"J"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0b013e3181d1e989","article-title":"The influence of nutritional status on the response to HAART in HIV-infected children in South Africa","volume":"29","author":"R Naidoo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"ref48","first-page":"790786","article-title":"Challenges in the Management of HIV-infected malnourished children in Sub-Saharan Africa","volume":"2012","author":"I Trehan","year":"2012","journal-title":"AIDS Res Ther"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00228-010-0851-0","article-title":"A systematic review of pharmacokinetics studies in children with protein\u2013energy malnutrition","volume":"66","author":"KA Oshikoya","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(08)60565-6","article-title":"Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence","volume":"371","author":"GT Heikens","year":"2008","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3182427029","article-title":"Unresolved antiretroviral treatment management issues in HIV-infected children","volume":"59","author":"S Heidari","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/QCO.0b013e328349287d","article-title":"Interactions of diarrhea, pneumonia, and malnutrition in childhood: recent evidence from developing countries","volume":"24","author":"EP Schlaudecker","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archinte.160.8.1123","article-title":"Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe Results from the EuroSIDA Study","volume":"160","author":"R Paredes","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00002030-200001280-00009","article-title":"Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor","volume":"14","author":"S Grabar","year":"2000","journal-title":"AIDS"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-200201040-00004","article-title":"Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen","volume":"16","author":"V Le Moing","year":"2002","journal-title":"AIDS"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e62408","DOI":"10.1371\/journal.pone.0062408","article-title":"Incidence and Associated Factors of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving Antiretroviral Treatment","volume":"8","author":"H Xing","year":"2013","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00002030-200101050-00008","article-title":"The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4\u20138 viral load","volume":"15","author":"AC Lepri","year":"2001","journal-title":"AIDS"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/651454","article-title":"Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis","volume":"201","author":"C Reitz","year":"2010","journal-title":"J Infect Dis"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0b013e32833f9e04","article-title":"Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART","volume":"25","author":"BC Zanoni","year":"2011","journal-title":"AIDS"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/QAI.0000000000000284","article-title":"The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children","volume":"67","author":"H Soeters","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0300-1652.149170","article-title":"Factors associated with antiretroviral treatment interruption in human immunodeficiency virus (HIV)-1-infected children attending the Jos University Teaching Hospital, Jos, Nigeria","volume":"56","author":"AO Ebonyi","year":"2015","journal-title":"Niger Med J"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"M Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/INF.0b013e3181af829d","article-title":"Protease inhibitor resistance in South African children with virologic failure","volume":"28","author":"GU Van Zyl","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/aid.2010.0205","article-title":"Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa","volume":"27","author":"BS Taylor","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/INF.0b013e31829f2694","article-title":"Consequences of prior use of full-dose ritonavir as single protease inhibitor as part of combination antiretroviral regimens on the future therapy choices in HIV-1 infected children","volume":"33","author":"UD Feucht","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 4","key":"ref66","doi-asserted-by":"crossref","first-page":"18086","DOI":"10.7448\/IAS.15.6.18086","article-title":"Evolution of resistance in paediatric patients with failure on antiretroviral therapy. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection","volume":"15","author":"C Orrell","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis","volume":"47","author":"Y Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00228-010-0847-9","article-title":"Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children","volume":"66","author":"D Elsherbiny","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"CJL LaPorte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1915","article-title":"Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children","volume":"17","author":"C Zhang","year":"2012","journal-title":"Antivir Ther"},{"key":"ref71","first-page":"185","article-title":"Notice to Readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors","volume":"49","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"AM Baciewicz","year":"2008","journal-title":"Am J Med Sci"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dku382","article-title":"Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir\/ritonavir","volume":"70","author":"H Moultrie","year":"2015","journal-title":"J. Antimicrob. Chemother"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/jac\/dki356","article-title":"Angeles Mu\u00f1oz-Fern\u00e1ndez M on behalf of the Spanish Group of Paediatric HIV infection. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir\/ritonavir therapy","volume":"56","author":"J Luis Jim\u00e9nez","year":"2005","journal-title":"J Antimicrob Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0133452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:29:47Z","timestamp":1717990187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0133452"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":74,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0133452","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]}}}